Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease

Conclusions/interpretationThe observed reduction in TNFR1, IL-6, MMP7 and FN1 suggests that canagliflozin contributes to reversing molecular processes related to inflammation, extracellular matrix turnover and fibrosis.Trial registration ClinicalTrials.gov NCT00968812

http://link.springer.com/10.1007/s00125-019-4859-4

Source: Diabetologia - April 16, 2019 Category: Endocrinology Source Type: research